Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DNA · against 492 other Healthcare companies of similar size
Ranked #417 of 493 · scores higher than 15% of peers · safety percentile 17
Bars: peers in each 10-point band of the safety percentile (higher = safer; 67+ earns the lower-risk grade)45 peers with a safety percentile of 10–19, including DNA · Click a bar to see the companies
Mainly because of its beta and debt / equity, which are weaker than most Healthcare peers.
Risk is relative to the sector, not a bankruptcy probability. Banks and brokers carry high leverage by design, and share buybacks can shrink equity and current assets, which raises debt/equity on paper.
| Metric | DNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Debt / equityLower is better · 462 reported | 0.96× | 0.17× | 12% | 33% | |
| BetaLower is better · 470 reported | 1.79 | 0.42 | 5% | 33% | |
| Current ratioHigher is better · 486 reported | 4.57× | 2.87× | 67% | 33% |
| Rank | Company | Market cap | Safety | Overall |
|---|---|---|---|---|
| 1 | 1.2B USD | 100 | 40 | |
| 2 | 1.1B USD | 100 | ||
| 3 | 1.0B USD | 99 | 35 | |
| 4 | 421M USD | 99 | 52 | |
| 5 | 1.2B USD | 99 | ||
| 413 | 5.1B CNY (≈$709M) | 18 | 12 | |
| 414 | 588M USD | 18 | 24 | |
| 415 | 771M EUR (≈$848M) | 17 | 53 | |
| 416 | 3.5B CNY (≈$496M) | 17 | 38 | |
| 417 | 725M USD | 17 | 19 | |
| 418 | 578M USD | 17 | 22 | |
| 419 | 1.18T KRW (≈$847M) | 17 | 63 | |
| 420 | 595M USD | 17 | 29 | |
| 421 | 1.3B USD | 16 | 33 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score